One reason immunotherapies can fail in cancer is that the tumor microenvironment can suppress activation of the immune system. Surface Oncology is using multiple platform technologies to discover new antibody therapies that activate both the innate and adaptive immune systems to improve how people with cancer respond to these medicines. We spoke to Rob Ross, CEO of Surface Oncology, about the tumor microenvironment, the approach Surface is taking to activate both the adaptive and innate immune system, and its lead therapeutic candidates in development.